Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Medixair® System on Surgical Site Infection in Cardiac Patients

24 de septiembre de 2015 actualizado por: F. Javier Alvarez, University of Valladolid

Impact of Medixair® System on Surgical Site Infection in Patients Admitted Into the Postoperative Cardiac Intensive Care Unit

There is a growing incidence of sepsis and septic shock in people after surgery, for which there may be several reasons: more elderly people and more severe illnesses are entering operating theatres, more invasive systems are being used to take care of patients in intensive care units, etc... Sepsis and septic shock are the most prevalent illnesses which cause the highest mortality in intensive care units.

The incidence of this illness is 500,000 / year in the USA, and 240-400 / 100,000 persons in Europe. So this is a subject of great interest in hospitals and also to the National Health System (to both health workers and the health authorities) as a lot of money is spent on this illness.

Since the 19th century, ultraviolet rays have been known to be able to sterilize microorganisms (to kill them); yet no ultraviolet system machine has been on the market, until now, to control nosocomial infections.

The Medixair system, which aims to do this, has recently come on to the market. It uses C-ultraviolet rays, which are the strongest kind of ultraviolet rays to kill microorganisms.

Thus, it is of interest to know whether this system is good enough to lower infections in intensive care units. It is logical to believe that the the fewer the micro-organisms, the lower the possibilities of infection.

Descripción general del estudio

Estado

Terminado

Intervención / Tratamiento

Descripción detallada

Study design Prospective, comparative, randomized, non intervention study

Patients

Patients older than 18 years

Cardiac Surgery anesthetized using Extracorporeal Circulation

Randomization

There are 10 independent boxes at the Postoperative Cardiac Intensive Care Unit. (Each of these boxes have single beds). Every year, the Cardiac Reanimation Unit of our hospital received 500 patients, post heart surgery.

After getting the permissions needed to make the research, the Medixair® system has been placed in 5 of these units, and the comparison group will be the other 5 beds without Medixair®. Patients have been assigned randomly to either (Medixair® and NO Medixair®).

The endpoint is:

-To compare the infection rates after a cardiac surgery, on patients located in boxes with and without a Medixair® system.

The aim is to see if there are fewer catheter infections, less bacteraemia, fewer urinary infections, less site of surgery infections, and fewer pneumonias in patients who have spent their first days after a heart surgery in a box with Medixair® system than without it. The infection rates in the intensive care unit will be followed, as well as the whole stay at hospital, as there might be fewer infections if there were fewer microorganisms around.

Other objectives are:

  • Identifying preoperative, intraoperative and postoperative risk factors to develop an infection illness after cardiac surgery, as well as which increase the length of stay at hospital and the mortality rate.
  • Making an economic study of using this system against not using it.

A further aim is to measure the following variables:

  • Dependent variables (Outcome variables): infection
  • 2º Outcome variables: colonization
  • Independent variables will be a risk factor for infection:
  • Preoperative: age, sex, any preoperative illness, immunosuppressor treatment, including corticosteroids.
  • Intraoperative: antibiotic prophylaxis, surgical technique, length of cardiopulmonary bypass, length of aorta clamped, temperature during cardiopulmonary bypass, hematocrit at the end of cardiopulmonary bypass.
  • Postoperative: length with mechanical ventilation, time spent in hospital, time spent in an intensive care unit, any organ complication (pulmonary insufficiency, renal failure, low cardiac index), septicemia, invasive techniques used, positive microorganism cultures.

All of the patients will be treated in the same way

Estimated number of patients

Nowadays, the infection rate after cardiac surgery is around 5%, so following the current hypothesis that the Medixair® system, because of its ultraviolet emissions, is going to lower the infection rate after cardiac surgery, 419 patients are needed in each group to be able to demonstrate a significative 5% reduction in infection rates, with an alpha error of 0.05 and a beta error of 0.2 to have a power of 80%.

As this is a preliminary study, in order to demonstrate a 5% reduction in the infection rate, half the number of patients (half of 419) will be used. As the patient volume is 500 a year, the number will be rounded up to 500, in order to be able to consider a complete year.

Tipo de estudio

Intervencionista

Inscripción (Actual)

1000

Fase

  • No aplica

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

18 años a 99 años (Adulto, Adulto Mayor)

Acepta Voluntarios Saludables

No

Géneros elegibles para el estudio

Todos

Descripción

Inclusion Criteria:

  • Patients admitted to Postoperative Cardiac Intensive Care Unit after Cardiac Surgery with Extracorporeal Circulation

Exclusion Criteria:

  • Not signing informed consent

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

  • Propósito principal: Cuidados de apoyo
  • Asignación: Aleatorizado
  • Modelo Intervencionista: Asignación paralela
  • Enmascaramiento: Ninguno (etiqueta abierta)

Armas e Intervenciones

Grupo de participantes/brazo
Intervención / Tratamiento
Experimental: Medixair®
Cardiac reanimation unit bed with Medixair®
Medixair system uses C-ultraviolet rays, which are the strongest ultraviolet kind of rays to kill microorganisms. The intervention consist consists of adding the Medixair® device, to be various beds of Cardiac Reanimation Units, or not.
Sin intervención: NO Medixair®
Cardiac reanimation unit bed with NO Medixair®

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Infection rates after cardiac surgery
Periodo de tiempo: 3 weeks
To assess if there are fewer catheter infections, less bacteraemia, fewer urinary infections, fewer surgery site infections, fewer pneumonias in patients who have spent their first days after a heart surgery in a box with the Medixair system than without it.
3 weeks

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Number of infected patients
Periodo de tiempo: 3 weeks
Number of infected patients
3 weeks
mortality rate
Periodo de tiempo: 3 weeks and for the whole stay at hospital
mortality rate
3 weeks and for the whole stay at hospital
number of patients with pneumonia
Periodo de tiempo: 3 weeks
number of patients with pneumonia
3 weeks

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Investigadores

  • Director de estudio: Eduardo Tamayo, PhD, MD, Hospital Clínico Universitario de Valladolid

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio

1 de enero de 2011

Finalización primaria (Actual)

1 de enero de 2015

Finalización del estudio (Actual)

1 de enero de 2015

Fechas de registro del estudio

Enviado por primera vez

4 de mayo de 2015

Primero enviado que cumplió con los criterios de control de calidad

6 de julio de 2015

Publicado por primera vez (Estimar)

9 de julio de 2015

Actualizaciones de registros de estudio

Última actualización publicada (Estimar)

25 de septiembre de 2015

Última actualización enviada que cumplió con los criterios de control de calidad

24 de septiembre de 2015

Última verificación

1 de septiembre de 2015

Más información

Términos relacionados con este estudio

Otros números de identificación del estudio

  • PI 14-176
  • 17-01-2011 (Otro identificador: Comision Investigacion HCUV)

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Ensayos clínicos sobre Medixair®

3
Suscribir